Quality of Life in Primary Biliary Cholangitis - Advances in the Treatment
DOI:
https://doi.org/10.12775/QS.2024.23.55038Keywords
quality of life, treatment advances, primary biliary cholangitis, treatment, ursodeoxycholic acid, cholestasis, inflammatory, activityAbstract
Primary sclerosing cholangitis (PSC) is an inflammatory, cholestatic and progressively fibrotic liver disease devoid of effective medical intervention. PBC is a presumed immune-mediated liver disease of middle-aged women associated with significant morbidity and mortality. People living with PBC are frequently symptomatic, experiencing a quality-of-life burden dominated by fatigue, itch, abdominal pain, and sicca complex. Many drugs have been studied for treatment, including agents with choleretic and immunosuppressive properties. Future PBC licensed therapy will likely include peroxisome proliferator activated receptor (PPAR) pathway agonists, including specific PPAR-delta agonism (seladelpar), as well as elafibrinor and saroglitazar (both with broader PPAR agonism). Effective therapy reduces the need for transplantation and improves life expectancy.
References
Carbone M, Gerussi A, Cardinale V, et al. Position paper of the Italian Association for the Study of the Liver (AISF): Management and treatment of primary biliary cholangitis, Digestive and Liver Disease
https://doi.org/10.1016/j.dld.2024.05.002
Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, et al. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med 2024;390:795-805
DOI: 10.1056/NEJMoa2306185
Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, Bonder A, Hirschfield GM, Levy C, Vierling J, Jones D, Tailleux A, Staels B, Megnien S, Hanf R, Magrez D, Birman P, Luketic V. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology 2021 vol. 74 j 1344–1354
https://doi.org/10.1016/j.jhep.2021.01.013
Kremer AE, Mayo MJ, Hirschfield GM, Levy C, Bowlus CL, Jones DE, Johnson JD, McWherter CA, Choi Y. Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology. 2024;80:27–37
DOI: 10.1097/HEP.0000000000000728
Naffouj S, Wang J. Current and future opportunities for the management of primary biliary cholangitis. Front. Gastroenterol. 2:1241901
doi: 10.3389/fgstr.2023.1241901
Hirschfield GM, Shiffman ML, Gulamhusein A, Vierling JM, Levy C, Kowdley KV, Kremer AE, et al. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023;78:397–415
DOI: 10.1097/HEP.0000000000000395
Levy C, Manns M, Hirschfield G. New Treatment Paradigms in Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology 2023;21:2076–2087
https://doi.org/10.1016/j.cgh.2023.02.005
Barba Bernal R, Ferrigno B, Medina Morales E, et al. Management of primary biliary cholangitis: Current treatment and future perspectives. Turk J Gastroenterol. 2023;34(2):89-100
DOI: 10.5152/tjg.2023.22239
van Hooff MC, Werner E, van der Meer AJ. Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid. European Journal of Internal Medicine 124 (2024) 14–21
https://doi.org/10.1016/j.ejim.2024.01.030
Jones DEJ, Beuers U, Bonder A, Carbone M, Culver E, Dyson J, Gish RG et al.
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here? Hepatology. 2024;00:000–000
DOI: 10.1097/HEP.0000000000000864
Lin W, Wang J, Liu Y. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis. Lin et al. Systematic Reviews (2024) 13:46
https://doi.org/10.1186/s13643-024-02460-0
Moehlen M. Emerging Treatment Strategies for Patients With Primary Biliary Cholangitis. Gastroenterol Hepatol (N Y). 2021 Dec;17(12):598-601.
PMID: 35465070; PMCID: PMC9021176
Puckey M. Iqirvo FDA Approval History [online]
https://www.drugs.com/history/iqirvo.html
FDA NEWS RELEASE. FDA Roundup: June 11, 2024 [online]
https://www.fda.gov/news-events/press-announcements/fda-roundup-june-11-2024
Boudes P, et al. Pharmacokinetics and pharmacodynamics of sela-delpar, a potent and selective PPAR-delta, in patients with primarybiliary cholangitis. J Hepatol. 2018;68.
Mao L, et al. FRI-041-Pharmacokinetics, safety, and tolerability ofseladelpar in subjects with hepatic impairment. J Hepatol. 2019;70(1).
Wetten A, Jones DEJ, Dyson JK; Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC); Expert Opin Investig Drugs. 2022 Oct;31(10):1101-1107. doi: 10.1080/13543784.2022.2130750. Epub 2022 Oct 8.
Jani RH, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A, et al. A
multicenter, prospective, randomized, double-blind study to evaluate the safety and
efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus
patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS
VI). Diabetes Technol Ther (2014) 16(2):63–71. doi: 10.1089/dia.2013.0253
Vuppalanchi R, Caldwell SH, Pyrsopoulos N, deLemos AS, Rossi S, Levy C, et al.
Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients
with primary biliary cholangitis. J Hepatol (2022) 76(1):75–85. doi: 10.1016/
j.jhep.2021.08.025
Méndez-Sánchez N, Coronel-Castillo CE, Ordoñez-Vázquez AL; Current Therapies for Cholestatic Diseases; Biomedicines 2023, 11(6), 1713; https://doi.org/10.3390/biomedicines11061713
Liang S, Kisseleva T, Brenner DA, The Role of NADPH Oxidases (NOXs) in Liver Fibrosis and the Activation of Myofibroblasts; Front Physiol. 2016; 7: 17. Published online 2016 Feb 2. doi: 10.3389/fphys.2016.00017
Huang B, Lyu Z, Qian Q; NUDT1 promotes the accumulation and longevity of CD103+ TRM cells in primary biliary cholangitis; Journal of Hepatology 2022 vol. 77 j 1311–1324
Hirschfield GM, Chazouilleres O, Drenth JP, Thorburn D, Harrison SA, Landis
CS, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A
multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol
(2019) 70(3):483–93. doi: 10.1016/j.jhep.2018.10.035
Gordon SC, Trudeau S, Regev A, Uhas JM, Chakladar S, Pinto-Correia A, et al.
Baricitinib and primary biliary cholangitis. J Transl Autoimmun (2021) 4:100107.
doi: 10.1016/j.jtauto.2021.100107
Jones DEJ, Beuers U, Bonder A; Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?; Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000 000864.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Agnieszka Kuzio, Aleksandra Cieplińska , Grzegorz Jama, Kinga Ziojła-Lisowska, Marzena Pliszka, Zuzanna Piasecka, Karolina Haczkur-Pawłowska, Maciej Borowiak, Patrycja Kolano, Patrycja Karnas-Bogacka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 174
Number of citations: 0
